Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide
1. 170569-88-7
2. Trocoxil
3. Pha-739521
4. Pha 739,521
5. Yft7x7sr77
6. Chembl28527
7. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide
8. Chebi:76207
9. Mavacoxib (usan)
10. Mavacoxib [usan]
11. 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide
12. 4-[5-(4-fluoro-phenyl)-3-trifluoromethyl-pyrazol-1-yl]-benzenesulfonamide
13. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide
14. Benzenesulfonamide, 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)-
15. Mavacoxib [usan:inn]
16. Unii-yft7x7sr77
17. Mavacoxibum
18. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
19. Mavacoxib [inn]
20. Mavacoxib [mi]
21. Schembl212699
22. Dtxsid90168880
23. Bcp15454
24. Zinc3814698
25. Bdbm50057564
26. Mfcd28138640
27. S6685
28. Akos030241943
29. At19475
30. Mavacoxib [ema Epar Veterinary]
31. Ncgc00510931-01
32. As-78391
33. Hy-119447
34. Cs-0068402
35. D04863
36. E-6113
37. Q6794110
38. 4-[5-(4-fluorophenyl)-3-trifluoromethyl-1h-pyrazol-1-yl]benzenesulfonamide
39. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-benzenesulfonamide
40. Pha-739521; Pha739521; Pha 739521; Pha 739,521; Pha739,521; Pha-739,521
| Molecular Weight | 385.3 g/mol |
|---|---|
| Molecular Formula | C16H11F4N3O2S |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 385.05081042 g/mol |
| Monoisotopic Mass | 385.05081042 g/mol |
| Topological Polar Surface Area | 86.4 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 579 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated.
QM01AH92
ABOUT THIS PAGE
A Mavacoxib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mavacoxib, including repackagers and relabelers. The FDA regulates Mavacoxib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mavacoxib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mavacoxib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mavacoxib supplier is an individual or a company that provides Mavacoxib active pharmaceutical ingredient (API) or Mavacoxib finished formulations upon request. The Mavacoxib suppliers may include Mavacoxib API manufacturers, exporters, distributors and traders.
click here to find a list of Mavacoxib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mavacoxib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mavacoxib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mavacoxib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mavacoxib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mavacoxib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mavacoxib suppliers with NDC on PharmaCompass.
Mavacoxib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mavacoxib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mavacoxib GMP manufacturer or Mavacoxib GMP API supplier for your needs.
A Mavacoxib CoA (Certificate of Analysis) is a formal document that attests to Mavacoxib's compliance with Mavacoxib specifications and serves as a tool for batch-level quality control.
Mavacoxib CoA mostly includes findings from lab analyses of a specific batch. For each Mavacoxib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mavacoxib may be tested according to a variety of international standards, such as European Pharmacopoeia (Mavacoxib EP), Mavacoxib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mavacoxib USP).
LOOKING FOR A SUPPLIER?
